The image appears to show a public notice from Alkem Laboratories Limited dated August 14, 2026, announcing the proposed discontinuation and stop of manufacturing or marketing for several scheduled formulations under paragraph 21(2) of the Drugs Price Control Order, 2013.Notice Details: Issued by Alkem Laboratories (signed by Nitin Agrawal, President & CFO - Finance) stating an intent to stop production/marketing of listed medicines after a period of six to twelve months.Medicines Listed: Includes common formulations such as Moxam-400 (Moxifloxacin), Sumol-500/650 (Paracetamol), Tamica-20/40/80 (Telmisartan), Alevo-250/500/750 (Levofloxacin), and various oncology, antibiotic, and suspension products.Patient Advice: Recommends that patients using these specific medicines consult their doctor for alternative prescriptions prior to market discontinuation. Make sure to double-check the physical label or official corporate announcements from Alkem Laboratories to confirm product availability and details.